FI925210A0 - Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda - Google Patents

Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda

Info

Publication number
FI925210A0
FI925210A0 FI925210A FI925210A FI925210A0 FI 925210 A0 FI925210 A0 FI 925210A0 FI 925210 A FI925210 A FI 925210A FI 925210 A FI925210 A FI 925210A FI 925210 A0 FI925210 A0 FI 925210A0
Authority
FI
Finland
Prior art keywords
modification
rna molecular
rna
aenda
foerfaranden
Prior art date
Application number
FI925210A
Other languages
English (en)
Other versions
FI925210A (fi
Inventor
Brenda F Baker
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of FI925210A publication Critical patent/FI925210A/fi
Publication of FI925210A0 publication Critical patent/FI925210A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI925210A 1990-05-23 1992-11-17 Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda FI925210A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23
PCT/US1991/003606 WO1991017755A1 (en) 1990-05-23 1991-05-22 Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna

Publications (2)

Publication Number Publication Date
FI925210A FI925210A (fi) 1992-11-17
FI925210A0 true FI925210A0 (fi) 1992-11-17

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
FI925210A FI925210A0 (fi) 1990-05-23 1992-11-17 Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda

Country Status (15)

Country Link
EP (1) EP0531447B1 (fi)
JP (1) JPH06500075A (fi)
KR (1) KR960004931B1 (fi)
AT (1) ATE186464T1 (fi)
AU (1) AU649458B2 (fi)
BR (1) BR9106486A (fi)
CA (1) CA2083377C (fi)
DE (1) DE69131773T2 (fi)
DK (1) DK0531447T3 (fi)
ES (1) ES2139578T3 (fi)
FI (1) FI925210A0 (fi)
GR (1) GR3032457T3 (fi)
HU (1) HUT63568A (fi)
NO (1) NO924309D0 (fi)
WO (1) WO1991017755A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
EP0691853B1 (en) * 1993-04-01 2002-06-05 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
AU2001239856A1 (en) * 2000-02-25 2001-09-03 Tao Biosciences, Llc Platform for the discovery of the bacterial genes involved in rna modification
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0604409B1 (en) * 1990-01-11 2004-07-14 Isis Pharmaceuticals, Inc. Oligonucleotide analogs for detecting and modulating rna activity and gene expression

Also Published As

Publication number Publication date
DE69131773T2 (de) 2000-03-02
HUT63568A (en) 1993-09-28
EP0531447A1 (en) 1993-03-17
FI925210A (fi) 1992-11-17
BR9106486A (pt) 1993-05-25
DK0531447T3 (da) 2000-03-27
EP0531447A4 (en) 1993-08-11
CA2083377C (en) 2002-11-26
KR930700118A (ko) 1993-03-13
JPH06500075A (ja) 1994-01-06
HU9203659D0 (en) 1993-04-28
NO924309L (no) 1992-11-09
AU649458B2 (en) 1994-05-26
GR3032457T3 (en) 2000-05-31
AU8080291A (en) 1991-12-10
CA2083377A1 (en) 1991-11-24
KR960004931B1 (ko) 1996-04-18
DE69131773D1 (de) 1999-12-16
NO924309D0 (no) 1992-11-09
ES2139578T3 (es) 2000-02-16
ATE186464T1 (de) 1999-11-15
EP0531447B1 (en) 1999-11-10
WO1991017755A1 (en) 1991-11-28

Similar Documents

Publication Publication Date Title
FI925210A (fi) Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda
DE69433626D1 (de) N-2 substituierte purine
ATE174599T1 (de) Bindungskompetente oligomere, die 2',5'-bindungen enthalten
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
ES2185695T3 (es) Terapia genica dirigida.
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
KR920004570A (ko) 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법
FI103577B1 (fi) Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamiseksi
ATE295885T1 (de) Endo-xyloglucan-transferase
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
AU7974791A (en) Identification of novel drugs and reagents
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
DK1235916T3 (da) Isolerede polynukleotider med et formindsket indhold af 5'CpG3' epigenitiske kontrolmotiver og anvendelser deraf
WO1993013204A3 (de) Mittel zur stimulierung der teilungsaktivität tierischer zellen
WO1999027088A3 (en) Novel gene and protein expressed in neural and pancreatic tissues
AU2782989A (en) Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
EP1074619A3 (en) Promoter for neuropeptide FF and use thereof for therapy and diagnostics
Gallagher et al. Enzymic cleavage of purine ultraviolet photoproducts formed at biologically significant wavelengths
DE69830895D1 (de) Verfahren zur Herstellung von humanen [alpha] Leukozyteninterferon

Legal Events

Date Code Title Description
FD Application lapsed